Tetra commences PoC clinical trial of PPP003v for companion dogs

Tetra commences PoC clinical trial of PPP003v for companion dogs

Date: 2020-02-22 By Saipriya Iyer

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in veterinary setting. R....

Satipharm begins clinical trial of CBD capsules for treating menopause

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting advanced clinical trials ....

Walmart reveals international sales numbers; Flipkart leads the chart

American multinational retail company, Walmart, Inc. has recently revealed that ecommerce has led to 12% to its international sales. Apparently, these sales were led by its online grocery delivery platform and Flipkart. In its Q4 earnings ....

Recardio announces conclusion of interim analysis of Phase 2 in AMI

  The study of combination of dutogliptin and filgrastim involved approximately 120 patient enrollments. The company expects the trial completion by year end. Treatment trials across various pharmaceutical companies are on the go....

Carrefour acquires 30 Makro stores to expand footprint in Brazil

Grupo Carrefour Brasil, the Brazilian unit of France’s Carrefour SA, has accelerated the expansion of the Atacadão format by acquiring 30 Cash & Carry stores of Makro Atacadista SA. The transaction was valuated at 1.95 Bn ....

Voyager Digital buys Circle Invest to expand retail customer base

Voyager Digital Canada Ltd. – a digital wealth management firm based in New York, United States has reportedly signed an agreement to purchase Circle Invest- a digital asset management subsidiary of Circle Internet Financial, Inc. Fo....

CytRx publishes results from Arimoclomol Phase 2 trial for sIBM

CytRx Corporation, a biopharmaceutical firm that specializes principally in neurodegenerative and oncology diseases, recently announced its data from Orphazyme double-blinded Phase 2 study of arimoclomol for the treatment of sIBM (Sporadic ....

Industry Updates